Browse our 1,000+ Publications​

Latest Publications

Immunosequencing and Profiling of T Cells at the Maternal-Fetal Interface of Women with Preterm Labor and Chronic Chorioamnionitis

Miller D, et al.
Journal of Immunology
October 2023
immuneAccess
Authors and Affiliates
Derek Miller 1,2, Roberto Romero 1,3,4, Luke Myers 5, Yi Xu 1,2, Marcia Arenas-Hernandez 1,2, Jose Galaz 1,2,6, Cinque Soto 5,7, Bogdan Done 1,2, Angelica Quiroz 1, Awoniyi O Awonuga 2, David R Bryant 2, Adi L Tarca 1,2,8,9, Nardhy Gomez-Lopez 1,2,10,9; 1 Pregnancy Research Branch, Division of Obstetrics and Maternal-Fetal Medicine, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, MD. 2 Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, MI. 3 Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI. 4 Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, MI. 5 Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN. 6 Division of Obstetrics and Gynecology, Faculty of Medicine, Pontificial Catholic University of Chile, Santiago, Chile. 7 Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN. 8 Department of Computer Science, Wayne State University College of Engineering, Detroit, MI. 9 Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, Detroit, MI. 10 Department of Biochemistry, Microbiology, and Immunology, Wayne State University School of Medicine, Detroit, MI.

TRAF2/3 deficient B cells resist DNA damage-induced apoptosis via NF-κB2/XIAP/cIAP2 axis and IAP antagonist sensitizes mutant lymphomas to chemotherapeutic drugs

Vashisht M, et al.
Cell Death and Disease
October 2023
Authors and Affiliates
Monika Vashisht 1, Huaibin Ge 1, Jessy John 1, Harlie A McKelvey 1, Jingxin Chen 1, Zhangguo Chen 2, Jing H Wang 3,4; 1 UPMC Hillman Cancer Center, Division of Hematology and Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, 15213, USA. 2 UPMC Hillman Cancer Center, Division of Hematology and Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, 15213, USA. zhc90@pitt.edu. 3 UPMC Hillman Cancer Center, Division of Hematology and Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, 15213, USA. JHW51@pitt.edu. 4 Department of Immunology, University of Pittsburgh, Pittsburgh, PA, 15213, USA. JHW51@pitt.edu.

Persistence of ex vivo expanded tumour and pathogen specific T-cells after allogeneic stem cell transplant for myeloid malignancies (the INTACT study)

Jiang W, et al.
Leukemia
October 2023
Authors and Affiliates
Wei Jiang 1,2, Selmir Avdic 1,2, Koon H Lee 1,2,3, Janine Street 2, Gloria Castellano-González 2, Renee Simms 1,2, Leighton E Clancy 4, Richard Blennerhassett 3, Ellis Patrick 2,5, Adam S Chan 5,6, Helen M McGuire 6,7, Nadav Myers 2, Brian S Gloss 2, Melissa Gabriel 8, Caroline M Bateman 1,2,8, Ken Micklethwaite 1,2,3,9, David J Gottlieb 1,2,3, Emily Blyth 10,11,12; 1 Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Camperdown, NSW, Australia. 2 Westmead Institute for Medical Research, The University of Sydney, Westmead, NSW, Australia. 3 Blood Transplant and Cell Therapies Program, Department of Haematology, Westmead Hospital, Westmead, NSW, Australia. 4 Research and Education Network, Western Sydney Area Health Service, Westmead, NSW, Australia. 5 School of Mathematics and Statistics, Faculty of Science, University of Sydney, Camperdown, NSW, Australia. 6 Charles Perkins Centre, The University of Sydney, Camperdown, NSW, Australia. 7 Infection, Immunity and Inflammation Theme, School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia. 8 Blood Transplant and Cell Therapies Unit, The Children's Hospital at Westmead, Westmead, NSW, Australia. 9 Blood Transplant and Cell Therapies Laboratory, Institute for Pathology and Medical Research, NSW Health Pathology, Westmead, NSW, Australia. 10 Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Camperdown, NSW, Australia. emily.blyth@sydney.edu.au. 11 Westmead Institute for Medical Research, The University of Sydney, Westmead, NSW, Australia. emily.blyth@sydney.edu.au. 12 Blood Transplant and Cell Therapies Program, Department of Haematology, Westmead Hospital, Westmead, NSW, Australia. emily.blyth@sydney.edu.au.

NAIR: Network Analysis of Immune Repertoire

Yang H, et al.
Frontiers in Immunology
October 2023
Authors and Affiliates
Hai Yang 1, Jason Cham 2, Brian Patrick Neal 1,3, Zenghua Fan 3, Tao He 4, Li Zhang 1,3,5; 1 Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, United States. 2 Department of Medicine, Scripps Green Hospital, La Jolla, CA, United States. 3 Department of Medicine, University of California San Francisco, San Francisco, CA, United States. 4 Department of Mathematics, San Francisco State University, San Francisco, CA, United States. 5 Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, United States.

Longitudinal change trend of the TCR repertoire reveals the immune response intensity of the inactivated COVID-19 vaccine

Ren C, et al.
Molecular Immunology
October 2023
Authors and Affiliates
Chengsi Ren 1, Ruili Ji 2, Yizhe Li 3, Jinyong He 4, Wei Hu 4, Xiangyun Teng 5, Jiahui Gao 4, Yue Wu 4, Jianhua Xu 6; 1 Department of Laboratory Medicine, Shunde Hospital of Guangzhou University of Chinese Medicine, Foshan, China. Electronic address: zyyrcs@163.com. 2 Department of Laboratory Medicine, Shunde Hospital of Guangzhou University of Chinese Medicine, Foshan, China. Electronic address: jiruili0302@163.com. 3 West China TianFu Hospital,Sichuan University, Chengdu, China. Electronic address: liyizhe1203@163.com. 4 Department of Laboratory Medicine, Shunde Hospital of Guangzhou University of Chinese Medicine, Foshan, China. 5 Medical Laboratory Center, Maoming Hospital of Guangzhou University of Chinese Medicine, Maoming, China; Translational Medicine Research Center, Maoming Hospital of Guangzhou University of Chinese Medicine, Maoming, China. 6 Department of Laboratory Medicine, Shunde Hospital of Guangzhou University of Chinese Medicine, Foshan, China; Medical Laboratory Center, Maoming Hospital of Guangzhou University of Chinese Medicine, Maoming, China; Translational Medicine Research Center, Maoming Hospital of Guangzhou University of Chinese Medicine, Maoming, China. Electronic address: jhxu1976@gzucm.edu.cn.

Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma

Coffey DG, et al.
Nature Communications
October 2023
immuneAccess
Authors and Affiliates
David G Coffey 1,2, Francesco Maura 3, Edgar Gonzalez-Kozlova 4, J Javier Diaz-Mejia 5, Ping Luo 5, Yong Zhang 6, Yuexin Xu 7, Edus H Warren 7, Travis Dawson 4, Brian Lee 4, Hui Xie 4, Eric Smith 8, Amanda Ciardiello 9, Hearn J Cho 4,10, Adeeb Rahman 4, Seunghee Kim-Schulze 4, Benjamin Diamond 3, Alexander Lesokhin 9, Dickran Kazandjian 3, Trevor J Pugh 5,11,12, Damian J Green 7, Sacha Gnjatic 4, Ola Landgren 13; 1 Division of Myeloma, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA. davidcoffey@miami.edu. 2 Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. davidcoffey@miami.edu. 3 Division of Myeloma, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA. 4 Icahn School of Medicine at Mount Sinai, New York, NY, USA. 5 Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. 6 Office of Oncologic Diseases, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA. 7 Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 8 Dana-Farber Cancer Institute, Boston, MA, USA. 9 Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 10 Multiple Myeloma Research Foundation, Norwalk, USA. 11 Ontario Institute for Cancer Research, Toronto, ON, Canada. 12 Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada. 13 Division of Myeloma, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA. col15@miami.edu.

Tumor-infiltrating normal B cells revealed by immunoglobulin repertoire clonotype analysis are highly prognostic and crucial for antitumor immune responses in DLBCL

Xu-Monette ZY, et al.
Clinical Cancer Research
October 2023
Authors and Affiliates
Zijun Y Xu-Monette 1, Yong Li 2, Thomas Snyder 3, Tiantian Yu 4, Tingxun Lu 5, Alexandar Tzankov 6, Carlo Visco 7, Govind Bhagat 8, Wenbin Qian 9, Karen Dybkaer 10, April Chiu 11, Wayne Tam 12, Youli Zu 13, Eric D Hsi 14, Fredrick B Hagemeister 15, Yingjun Wang 16, Heounjeong Go 17, Maurilio Ponzoni 18, Andrés J M Ferreri 19, Michael B Moller 20, Benjamin M Parsons 21, Xiangshan Fan 22, J Han van Krieken 23, Miguel A Piris 24, Jane N Winter 25, Qingyan Au 26, Ilan Kirsch 27, Mingzhi Zhang 28, John Shaughnessy 29, Bing Xu 30, Ken H Young 31; 1 Duke University, Durham, North Carolina, United States. 2 Baylor College of Medicine, Houston, United States. 3 Adaptive Biotechnologies (United States), Seattle, United States. 4 Second Affiliated Hospital of Nanchang University, Nanchang, China. 5 Duke University, Durham, United States. 6 University of Basel, Hospital, Basel, Switzerland. 7 University of Verona, Verona, Italy. 8 Columbia University Medical Center, New York, NY, United States. 9 Second Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China. 10 Aalborg University Hospital, Aalborg,, Denmark. 11 Mayo Clinic, Rochester, MN, United States. 12 Weill Cornell Medicine, New York, NY, United States. 13 Houston Methodist, HOUSTON, Texas, United States. 14 Wake Forest University School of Medicine, Winston-Salem, NC, United States. 15 The University of Texas MD Anderson Cancer Center, Houston, TX, United States. 16 The University of Texas MD Anderson Cancer Center, United States. 17 Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea (South), Republic of. 18 San Raffaele Scientific Institute, Milano, Italy. 19 IRCCS San Raffaele Scientific Institute, Milano, MI, Italy. 20 Odense University Hospital, Odense, Denmark. 21 Gundersen Lutheran Health System, La Crosse, WI, United States. 22 First Affiliated Hospital of Anhui Medical University, China. 23 Radboud university medical centre, Nijmegen, Netherlands. 24 Fundacion Jimenez Diaz, Madrid, Madrid, Spain. 25 Feinberg School of Medicine, Northwestern University, Chicago, IL, United States. 26 NeoGenomics, United States. 27 Adaptive Biotechnologies (United States), Seattle, WA, United States. 28 First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. 29 University of Arkansas for Medical Sciences, Little Rock, AR, United States. 30 First Affiliated Hospital of Xiamen University, Xiamen, China. 31 Duke University, Durham, NC, United States.

CDK4/6 inhibition sensitizes intracranial tumors to PD-1 blockade in preclinical models of brain metastasis

Nayyar N, et al.
Clinical Cancer Research
October 2023
immuneAccess
Authors and Affiliates
Naema Nayyar 1, Magali A de Sauvage 1, Jane Chuprin 2, Emily M Sullivan 3, Mohini Singh 1, Consuelo Torrini 4, Britney S Zhang 3, Sushobhana Bandyopadhyay 2, Keith A Daniels 2, Christopher Alvarez-Breckenridge 5, Ashish Dahal 6, Michael A Brehm 2, Priscilla K Brastianos 7; 1 Massachusetts General Hospital, Boston, MA, United States. 2 University of Massachusetts Chan Medical School, Worcester, MA, United States. 3 Massachusetts General Hospital, Boston, United States. 4 Massachusetts General Hospital, BOSTON, United States. 5 The University of Texas MD Anderson Cancer Center, Houston, United States. 6 Harvard Medical School & Massachusetts General Hospital, Boston, MA, United States. 7 Massachusetts General Hospital, Boston, Massachusetts, United States.

Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase 1b Trial

Nawrocki ST, et al.
Clinical Cancer Research
October 2023
Authors and Affiliates
Steffan T Nawrocki 1, Julian Olea 2, Claudia Villa Celi 3, Homa Dadrastoussi 4, Kaijin Wu 4, Denice Tsao-Wei 5, Anthony Colombo 6, Matthew Coffey 7, Eduardo Fernandez Hernandez 8, Xuelian Chen 9, Gerard J Nuovo 10, Jennifer S Carew 11, Ann F Mohrbacher 2, Paul Fields 12, Peter Kuhn 2, Imran Siddiqi 13, Akil Merchant 14, Kevin R Kelly 4; 1 University of Arizona Cancer Center, Tucson, AZ, United States. 2 University of Southern California, Los Angeles, CA, United States. 3 Capital Health, Hamilton, NJ, United States. 4 USC Norris Comprehensive Cancer Center, Los Angeles, CA, United States. 5 USC Keck School of Medicine/Norris Comprehensive Cancer Center, Los Angeles, California, United States. 6 Cedars-Sinai Medical Center, Los Angeles, CA, United States. 7 Oncolytics Biotech (Canada), Calgary, Alberta, Canada. 8 USC Norris Cancer Hospital, Los Angeles, CA, United States. 9 University of Southern California, LOS ANGELES, California, United States. 10 The Ohio State University, Columbus, OH, United States. 11 University of Arizona Cancer Center, Tucson, Arizona, United States. 12 Adaptive Biotechnologies (United States), Seattle, WA, United States. 13 University of Southern California Keck School of Mdicine, Los Angeles, CA, United States. 14 Cedars-Sinai Medical Center, Los Angeles, United States.

Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial.

Bahlis, N, et al.
Nature Medicine
October 2023
Authors and Affiliates
Nizar J Bahlis, Caitlin L Costello, Noopur S Raje, Moshe Y Levy, Bhagirathbhai Dholaria, Melhem Solh, Michael H Tomasson, Michael A Damore, Sibo Jiang, Cynthia Basu, Athanasia Skoura, Edward M Chan, Suzanne Trudel, Andrzej Jakubowiak, Cristina Gasparetto, Michael P Chu, Andrew Dalovisio, Michael Sebag, Alexander M Lesokhin
Previous Next